{"@type": "dcat:Dataset", "accessLevel": "public", "accrualPeriodicity": "R/P1Y", "bureauCode": ["009:10"], "contactPoint": {"@type": "vcard:Contact", "fn": "Division of Drug Information", "hasEmail": "mailto:druginfo@fda.hhs.gov"}, "description": "Rivaroxaban is a prescription oral tablet medication that acts as a Factor Xa inhibitor to help prevent blood clots. It is available in strengths of 2.5 mg, 10 mg, 15 mg, and 20 mg, manufactured by Florida Pharmaceutical Products, LLC under application ANDA218445. This information was generated using AI and is provided for informational and research purposes only.", "distribution": [{"@type": "dcat:Distribution", "description": "\n        Access the FDA dataset for Rivaroxaban \u2014 ANDA 022406 submitted by Mylan Institutional LLC\n    ", "downloadURL": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022406", "mediaType": "text/html", "title": "Rivaroxaban"}], "identifier": "ANDA022406", "issued": "2016-09-16", "keyword": ["drug-information", "drug-safety", "health-care", "medications", "prescription-drugs"], "landingPage": "https://www.fda.gov/drugs", "license": "https://open.fda.gov/license", "modified": "2025-03-17", "programCode": ["009:002"], "publisher": {"@type": "org:Organization", "name": "U.S. Food and Drug Administration"}, "theme": ["FDA"], "title": "Rivaroxaban"}